Emergency management of atrial fibrillation

Postgraduate Medical Journal

Volumn 79, Issue 932, 2003, Pages 313-319

  Wakai, A ^a   O'Neill, J O ^b  

^a BEAUMONT HOSPITAL   (Ireland)

^b Our Lady's Hospital   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DILTIAZEM; DISOPYRAMIDE; ESMOLOL; IBUTILIDE; METOPROLOL; PROCAINAMIDE; PROPRANOLOL; QUINIDINE; VERAPAMIL;

ANTICOAGULATION; CARDIOVERSION; EMERGENCY TREATMENT; EVIDENCE BASED MEDICINE; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; PATIENT CARE; PATIENT SELECTION; PRACTICE GUIDELINE; REVIEW;

AMBULATORY CARE; ATRIAL FIBRILLATION; CARDIOVASCULAR AGENTS; CLINICAL PROTOCOLS; ELECTRIC COUNTERSHOCK; EMERGENCIES; EMERGENCY SERVICE, HOSPITAL; HOSPITALIZATION; HUMANS; PATIENT SELECTION; RECURRENCE;

EID: 0038045264     PISSN: 00325473     EISSN: None     Source Type: Journal    
DOI: 10.1136/pmj.79.932.313     Document Type: Review

References (68)

1. Benjamin EJ, Levy D, Vaziri SM. Independent risk factors for atrial fibrillation in a population-based cohort: the Framingham Heart Study. JAMA 1994;271:840-4.
2. Benjamin EJ, Wolf PA, D'Agostino RB, et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998;98:946-52.
3. Prystowsky EN, Benson DW, Fuster V, et al. Management of patients with atrial fibrillation: a statement for healthcare professionals from the subcommittee on electrocardiography and electrophysiology, American Heart Association. Circulation 1996;93:1262-77.
4. Prystowsky EN. Tachycardia-induced tachycardia: a mechanism of initiation of atrial fibrillation. In: DiMarco JP, Prystowsky EN, eds. Atrial arrhythmias: state of the art. Armonk, NY: Futura Publishing Co, 1995.
5. Falk RH. Etiology and complications of atrial fibrillation: insights from pathology studies. Am J Cardiol 1998;82:10-17N.
6. Bialy D, Lehmann MH, Schumacher DN, et al. Hospitalisation of arrhythmias in the United States: importance of atrial fibrillation. J Am Coll Cardiol 1992;19:41A.
7. Prystowsky EN, Katz A. Atrial fibrillation. In: Topol EJ, ed. Textbook of cardiovascular medicine. 2nd Ed. Philadelphia: Lippincott Williams & Wilkins, 2002.
8. Connors S, Dorian P. Management of supraventricular tachycardia in the emergency department. Can J Cardiol 1997;13:19A-24.
9. Li H, Easley A, Barrington W, et al. Evaluation and management of atrial fibrillation in the emergency department. Emerg Med Clin North Am 1998;16:389-403.
10. Mulcahy B, Coates WC, Hennerman PL, et al. New-onset atrial fibrillation: when is admission medical justified? Acad Emerg Med 1996;3:114-19.
11. Feinberg WM, Blackshear JL, Laupacis A, et al. Prevalence, age distribution, and gender of patients with atrial fibrillation: analysis and implications. Arch Intern Med 1995;155:469-73.
12. The National Heart, Lung, and Blood Institute (NHLBI) Working Group on Atrial Fibrillation. Atrial fibrillation: current understandings and research imperatives. J Am Coll Cardiol 1993;22:1830-4.
13. Schreckengost VE, Zimetbaum PJ, Lemery R, et al. A prospective evaluation of the outpatient initiation of anti-arrhythmic drug therapy in patients with atrial fibrillation or flutter. Clin Cardiol 1997;suppl 1:1-454.
14. Hollander JE, Phibbs BP, Henneman PL, et al. Atrial fibrillation and hospital admission [letter]. Acad Emerg Med 1996;3:819-21.
15. Botto GL, Boninni W, Broffoni T, et al. Conversion of recent atrial fibrillation with a single loading dose of propafenone: is in-hospital admission absolutely necessary? PACE 1996;19:1939-43.
16. Michael JA, Steill IG, Agarwal S, et al. Cardioversion of paroxysmal atrial fibrillation in the emergency department. Ann Emerg Med 1999;33:379-87.
17. Koenig BO, Ross MA, Jackson RE. An emergency department observation unit protocol for acute-onset atrial fibrillation is feasible. Ann Emerg Med 2002;39:374-81.
18. Kim MH, Morady F, Conlon B, et al. A prospective, randomized controlled trial of an emergency department-based atrial fibrillation treatment strategy with low-molecular-weight heparin. Ann Emerg Med 2002;40:187-92.
19. Williams E, Ansari M, Lip GYH. Managing atrial fibrillation in the accident and emergency department. Q J Med 2001;94:609-14.
20. Fuster V, Rydén LE, Asinger RW, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and Policy Conferences (Committee to develop guidelines for the management of patients with atrial fibrillation) in collaboration with the North American Society of Pacing and Electrophysiology. Eur Heart J 2001;22:1852-923.
21. Falk RH. Atrial fibrillation. N Engl J Med 2001;344:1076-8.
22. Kopecky SL, Gersh BJ, McGoon MD, et al. Lone atrial fibrillation in elderly persons: a marker for cardiovascular risk. Arch Intern Med 1999;159:1118-22.
23. Prystowsky EN, Margiotti R, Fogel RI, et al. Atrial fibrillation with and without heart disease: clinical characteristics and proarrhythmia risk. Circulation 1996;94:1-191.
24. Haïssaguerre M, Jaïs P, Shah DC, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 1998;339:659-66.
25. Bharati S, Lev M. Histology of the normal and diseased atrium. In: Falk RH, Podrid PJ, eds. Atrial fibrillation: mechanisms and management. New York: Raven Press, 1992.
26. Chen YJ, Chen SA, Tai CT, et al. Role of atrial electrophysiology and autonomic nervous system in patients with supraventricular tachycardia and paroxysmal atrial fibrillation. J Am Coll Cardiol 1998;32:732-8.
27. Maixent JM, Paganelli F, Scaglione J, et al. Antibodies against myosin in sera of patients with idiopathic paroxysmal atrial fibrillation. J Cardiovasc Electrophysiol 1998;9:612-7.
28. Frustaci A, Chimenti C, Bellocci F, et al. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation 1997;96:1180-4.
29. Jouven X, Desnos M, Guerot C, et al. Idiopathic atrial fibrillation as a risk factor of mortally: the Paris Prospective Study I. Eur Heart J 1999;20:896-9.
30. Hamada T, Hiraki T, Ikeda H, et al. Mechanisms for atrial fibrillation in patients with Wolff-Parkinson-White syndrome. J Cardiovasc Electrophysiol 2002;13:223-9.
31. Weigner MJ, Caulfield TA. Risk of clinical thromboembolism associated with conversion to sinus rhythm in patients with atrial fibrillation lasting less than 48 hours. Ann Intern Med 1997;126:615-20.
32. Stoddard MF, Dawkins PR, Prince CR, et al. Left atrial appendage thrombus is not uncommon in patients with acute atrial fibrillation and a recent embolic event: a transesophageal echocardiographic study. J Am Coll Cardiol 1995;25:452-9.
33. Rawles JM. What is meant by a "controlled" ventricular rate in atrial fibrillation? Br Heart J 1990;63:157-61.
34. Manning WJ, Silverman DI, Katz SE, et al. Impaired left atrial mechanical function after cardioversion: relation to the duration of atrial fibrillation. J Am Coll Cardiol 1994;23:1535-40.
35. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002;347:1825-33.
36. Van Gelder IC, Hagens VE, Bosker HA, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002;347:1834-40.
37. Wijffels MCEF, Kirchhof CJHJ, Dorland R, et al. Atrial fibrillation begets atrial fibrillation: a study in awake chronically instrumented goats. Circulation 1995;92:1954-68.
38. Silverman DI, Manning WJ. Role of echocardiography in patients undergoing elective cardioversion of atrial fibrillation. Circulation 1998;98:479-86.
39. Berger M, Schweitzer P. Timing of thromboembolic events after electrical cardioversion of atrial fibrillation or flutter: a retrospective analysis. Am J Cardiol 1998;82:1545-7, A8.
40. Danias PG, Caulfield TA, Weigner MJ, et al. Likelihood of spontaneous conversion of atrial fibrillation to sinus rhythm. J Am Coll Cardiol 1998;31:588-92.
41. Reisinger J, Gatterer E, Heinze G, et al. Prospective comparison of flecainide versus sotalol for immediate cardioversion of atrial fibrillation. Am J Cardiol 1998;81:1450-4.
42. Lesser MF. Safety and efficacy of in-office cardioversion for treatment of supraventricular arrhythmias. Am J Cardiol 1990;66:1267-8.
43. Lévy S. Pharmacologic management of atrial fibrillation: current therapeutic strategies. Am Heart J 2001;141:S15-21.
44. Falk RH, Leavitt JI. Digoxin for atrial fibrillation: a drug whose time has gone? Ann Intern Med 1991;114:573-85.
45. Elam K, Bolar-Softich KL. Dilemmas in the acute pharmacologic treatment of uncontrolled atrial fibrillation. Am J Emerg Med 1997;15:418-9.
46. Barbier GH, Shettigar UR, Appunn DO. Clinical rationale for the use of an ultra-short acting beta-blocker: esmolol. Int J Clin Pharmacol Ther 1995;33:212-8.
47. Pritchett EL. Management of atrial fibrillation. N Engl J Med 1992;326:1264-71.
48. Clemo HF, Wood MA, Gilligan DM, et al. Intravenous amiodarone for acute heart rate control in the critically ill with atrial tachyarrhythmias. Am J Cardiol 1998;81:594-8.
49. Stambler BS, Wood MA, Ellenbogen KA, et al. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Circulation 1996;94:1613-21.
50. Cobbe SM, Rae AP, Poloniecki JD, et al. A randomized, placebo-controlled trial of propafenone in the prophylaxis of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation. Circulation 1995;92:2550-7.
51. Martinez-Marcos FJ, Garcia-Garmendia JL, Ortega-Carpio A, et al. Comparison of intravenous flecainide, propafenone, and amiodarone for conversion of acute atrial fibrillation to sinus rhythm. Am J Cardiol 2000;86:950-3.
52. Lee SH, Chen SA, Tai CT, et al. Comparisons of oral propafenone and sotalol as an initial treatment in patients with symptomatic paroxysmal atrial fibrillation. Am J Cardiol 1997;79:905-8.
53. Juul-Möller S, Edvardsson N, Rehnqvist-Ahlberg N. Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation. Circulation 1990;82:1932-9.
54. Volgman AS, Stambler BS, Kappagoda C, et al. Comparison of intravenous ibutilide versus procainamide for the rapid termination of atrial fibrillation or flutter [abstract]. PACE 1996;19:608.
55. Vos MA, Golitsin SR, Stangl K, et al. Superiority of ibutilide (a new class III agent) over DL-sotalol in converting atrial flutter and fibrillation. Heart 1998;79:568-73.
56. Ellenbogen KA, Stambler BS, Wood M, et al. Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: a dose-response study. J Am Coll Cardiol 1996;28:130-6.
57. Rawles JM, Metcalfe MJ, Jennings K. Time of occurrence, duration, and ventricular rate of paroxysmal atrial fibrillation: the effect of digoxin. The Cardiac Arrhythmia Suppression Trial. Br Heart J 1990;63:225-7.
58. Intravenous digoxin in acute atrial fibrillation. Results of a randomized, placebo- controlled multicentre trial in 239 patients. The Digitalis in Acute Atrial Fibrillation (DAAF) Trial Group. Eur Heart J 1997;18:649-54.
59. Jordaens L, Trouerbach J, Calle P, et al. Conversion of atrial fibrillation to sinus rhythm and rate control by digoxin in comparison to placebo. Eur Heart J 1997;18:643-8.
60. Li Saw Hee FL, Lip GYH. Digoxin revisited. Q J Med 1998;91:259-64.
61. Lip GYH. How would I manage a 60-year old woman presenting with atrial fibrillation? Proc Roy Coll Phys Edinb 1999;29:301-6.
62. Jung F, DiMarco JP. Treatment strategies for atrial fibrillation. Am J Med 1998;104:272-83.
63. Castro A, Biaconi L, Santini M. New antiarrhythmic drugs for the treatment of atrial fibrillation. Pacing Clin Electrophysiol 2002;25:249-59.
64. Prystowsky EN. Management of atrial fibrillation: therapeutic options and clinical decisions. Am J Cardiol 2000;85:3-11D.
65. Gosselink M, Crijns HJG, Van Gelder I, et al. Low-dose amiodarone for maintenance of sinus rhythm after cardioversion of atrial fibrillation or flutter. JAMA 1992;267:3289-93.
66. Kockiadakis G, Igoumenidis N, Solomou M, et al. Efficacy of amiodarone for the termination of persistent atrial fibrillation. Am J Cardiol 1999;83:58-61.
67. Kockiadakis G, Igoumenidis N, Parthenakis F, et al. Amiodarone versus propafenone for conversion of chronic atrial fibrillation: results of a randomized, controlled study. J Am Coll Cardiol 1999;33:966-71.
68. Zimetbaum PJ, Josephson ME, McDonald MJ, el al. Incidence and predictors of myocardial infarction among patients with atrial fibrillation. J Am Coll Cardiol 2000;36:1223-7.